Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2412083 | 0.99 | KDM4E (0.32) | KDM4EALDH1A1MAPTGSK3B | |
| SCHEMBL1581008 | 0.92 | PARP1 (0.33) | GSK3B | |
| SCHEMBL1763137 | 0.91 | TSHR (0.40) | KDM4EALDH1A1MAPTGSK3B | |
| Hydrochloric Acid SCHEMBL2410796 | 0.90 | TSHR (0.39) | KDM4EALDH1A1MAPTGSK3B | |
| SCHEMBL1762906 | 0.86 | KMT2A (0.30) | — | |
| SCHEMBL1580441 | 0.86 | GRIA2 (0.30) | — | |
| SCHEMBL5002632 | 0.86 | KDM4E (0.31) | KDM4EALDH1A1MAPT | |
| SCHEMBL5002630 | 0.86 | MAPT (0.30) | KDM4EALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL2410540 | 0.85 | GRIA2 (0.30) | — | |
| SCHEMBL1763034 | 0.85 | LMNA (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9186411-B2 | Pharmaceutical composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| US-20130261156-A1 | PHARMACEUTICAL COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-03 | — | — | US | disclosed |
| EP-2564833-A1 | Photostabilized pharmaceutical composition | Takeda Pharmaceutical Company Limited (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20110124687-A1 | PHARMACEUTICAL COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124687-A1 | PHARMACEUTICAL COMPOSITION | CYP2C19, MLST8, CYP3A43 | KDM4E 2790/4885ALDH1A1 1146/4885MAPT 539/4885 |
| US-20130261156-A1 | PHARMACEUTICAL COMPOSITION | CYP2C19, MLST8, CYP3A43 | KDM4E 2790/4885ALDH1A1 1146/4885MAPT 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.